Htd1801 (budca) (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04604652 (ClinicalTrials.gov) | November 30, 2020 | 16/10/2020 | Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis | A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC | Primary Biliary Cholangitis;Primary Biliary Cirrhosis;Cholangitis;Cholestasis;Biliary Tract Diseases;Bile Duct Stricture | Drug: HTD1801 (BUDCA) | HighTide Biopharma Pty Ltd | NULL | Recruiting | 18 Years | 75 Years | All | 30 | Phase 2 | United States |